JJ

Jun Jeon

Khosla Ventures - Healthcare, Biology, and Technology

San Francisco Bay Area

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Partner

    2025

  • Principal

    2023 - 2025

  • Associate

    2021 - 2023

    Partnering with entrepreneurs to build impactful, enduring companies.

2021 - 2021

  • Venture Fellow

    2021 - 2021

    Computational bio + lab-enabling technologies + healthcare / investing + ideating NewCo

2020 - 2021

  • Co-Founder / Co-Managing Director

    2020 - 2021

    bio-launch.com - later became Nucleate Philly Accelerating biotech venture formation from the ground up at the Unversity of Pennsylvania.

2021 - 2021

  • New Product Opportunities

    2021 - 2021

    Looking at the intersection of biology and commercial impact

2021 - 2021

  • Co-Managing Director and Co-founder of Philadelphia Chapter

    2021 - 2021

    Penn Bio Launch became Nucleate Philly Founding Co-Managing Directors with Eric and Sireesh, and oversaw leadership transition to the new org

2020 - 2021

  • Fellow / AVP of Startup Sourcing

    2020 - 2021

    Private equity fund in cybersecurity / managed IT services (healthcare focused)

2020 - 2020

  • Business Development

    2020 - 2020

    Leveraging pharmacy infrastructure towards new growth opportunities.

  • MRSP research fellowship

    2019 - 2020

    • Highly selective NIH-hosted research program for 50 medical students from across the US. • Focus on novel cancer therapeutics discovery pipeline, large genomic data analysis, immunotherapy, and hearing research.

2019 - 2020

  • Co-Founder, US-Korea International Startup Showcase

    2019 - 2020

    • Debuted a US-Korea international startup competition within an annual KSEA conference with 250+ participants. • Created and bilingually directed the competition for 20 early-to-mid stage startups (from US and Korea) and 5 VC judges.

  • Clinical research

    2016 - 2020

    • [EHR/eCRF data management] Phase 3 Remdesivir (COVID19 anti-viral) clinical trial at Penn • [Lead] Cochlear implant candidacy evaluation process quality improvement • [Lead] Brain tumor labeling with fluorescent dye for accurate resection